These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Rationale for targeting the pre-B-cell receptor signaling pathway in acute lymphoblastic leukemia. Müschen M Blood; 2015 Jun; 125(24):3688-93. PubMed ID: 25878119 [TBL] [Abstract][Full Text] [Related]
6. The pre-BCR to the rescue: therapeutic targeting of pre-B cell ALL. Trimarchi T; Aifantis I Cancer Cell; 2015 Mar; 27(3):321-3. PubMed ID: 25759017 [TBL] [Abstract][Full Text] [Related]
7. Activation-induced cytidine deaminase acts as a mutator in BCR-ABL1-transformed acute lymphoblastic leukemia cells. Feldhahn N; Henke N; Melchior K; Duy C; Soh BN; Klein F; von Levetzow G; Giebel B; Li A; Hofmann WK; Jumaa H; Müschen M J Exp Med; 2007 May; 204(5):1157-66. PubMed ID: 17485517 [TBL] [Abstract][Full Text] [Related]
8. Therapeutic potential of spleen tyrosine kinase inhibition for treating high-risk precursor B cell acute lymphoblastic leukemia. Perova T; Grandal I; Nutter LM; Papp E; Matei IR; Beyene J; Kowalski PE; Hitzler JK; Minden MD; Guidos CJ; Danska JS Sci Transl Med; 2014 May; 6(236):236ra62. PubMed ID: 24828076 [TBL] [Abstract][Full Text] [Related]
9. Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling. Myklebust JH; Brody J; Kohrt HE; Kolstad A; Czerwinski DK; Wälchli S; Green MR; Trøen G; Liestøl K; Beiske K; Houot R; Delabie J; Alizadeh AA; Irish JM; Levy R Blood; 2017 Feb; 129(6):759-770. PubMed ID: 28011673 [TBL] [Abstract][Full Text] [Related]
10. RAG-mediated DNA double-strand breaks activate a cell type-specific checkpoint to inhibit pre-B cell receptor signals. Bednarski JJ; Pandey R; Schulte E; White LS; Chen BR; Sandoval GJ; Kohyama M; Haldar M; Nickless A; Trott A; Cheng G; Murphy KM; Bassing CH; Payton JE; Sleckman BP J Exp Med; 2016 Feb; 213(2):209-23. PubMed ID: 26834154 [TBL] [Abstract][Full Text] [Related]
11. CD19 amplifies B lymphocyte signal transduction by regulating Src-family protein tyrosine kinase activation. Fujimoto M; Poe JC; Jansen PJ; Sato S; Tedder TF J Immunol; 1999 Jun; 162(12):7088-94. PubMed ID: 10358152 [TBL] [Abstract][Full Text] [Related]
12. Pre-B cell receptor-mediated activation of BCL6 induces pre-B cell quiescence through transcriptional repression of MYC. Nahar R; Ramezani-Rad P; Mossner M; Duy C; Cerchietti L; Geng H; Dovat S; Jumaa H; Ye BH; Melnick A; Müschen M Blood; 2011 Oct; 118(15):4174-8. PubMed ID: 21856866 [TBL] [Abstract][Full Text] [Related]
13. ZFP521 contributes to pre-B-cell lymphomagenesis through modulation of the pre-B-cell receptor signaling pathway. Hiratsuka T; Takei Y; Ohmori R; Imai Y; Ozeki M; Tamaki K; Haga H; Nakamura T; Tsuruyama T Oncogene; 2016 Jun; 35(25):3227-38. PubMed ID: 26522721 [TBL] [Abstract][Full Text] [Related]
14. BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Duy C; Hurtz C; Shojaee S; Cerchietti L; Geng H; Swaminathan S; Klemm L; Kweon SM; Nahar R; Braig M; Park E; Kim YM; Hofmann WK; Herzog S; Jumaa H; Koeffler HP; Yu JJ; Heisterkamp N; Graeber TG; Wu H; Ye BH; Melnick A; Müschen M Nature; 2011 May; 473(7347):384-8. PubMed ID: 21593872 [TBL] [Abstract][Full Text] [Related]
15. Syk and Bruton's tyrosine kinase are required for B cell antigen receptor-mediated activation of the kinase Akt. Craxton A; Jiang A; Kurosaki T; Clark EA J Biol Chem; 1999 Oct; 274(43):30644-50. PubMed ID: 10521450 [TBL] [Abstract][Full Text] [Related]
16. Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition. Köhrer S; Havranek O; Seyfried F; Hurtz C; Coffey GP; Kim E; Ten Hacken E; Jäger U; Vanura K; O'Brien S; Thomas DA; Kantarjian H; Ghosh D; Wang Z; Zhang M; Ma W; Jumaa H; Debatin KM; Müschen M; Meyer LH; Davis RE; Burger JA Leukemia; 2016 Jun; 30(6):1246-54. PubMed ID: 26847027 [TBL] [Abstract][Full Text] [Related]
17. Monovalent and multivalent ligation of the B cell receptor exhibit differential dependence upon Syk and Src family kinases. Mukherjee S; Zhu J; Zikherman J; Parameswaran R; Kadlecek TA; Wang Q; Au-Yeung B; Ploegh H; Kuriyan J; Das J; Weiss A Sci Signal; 2013 Jan; 6(256):ra1. PubMed ID: 23281368 [TBL] [Abstract][Full Text] [Related]
18. Mimicry of a constitutively active pre-B cell receptor in acute lymphoblastic leukemia cells. Feldhahn N; Klein F; Mooster JL; Hadweh P; Sprangers M; Wartenberg M; Bekhite MM; Hofmann WK; Herzog S; Jumaa H; Rowley JD; Müschen M J Exp Med; 2005 Jun; 201(11):1837-52. PubMed ID: 15939795 [TBL] [Abstract][Full Text] [Related]
19. Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway. Guo Y; Shan Q; Gong Y; Lin J; Yang X; Zhou R Cancer Biol Ther; 2012 Nov; 13(13):1244-54. PubMed ID: 22895079 [TBL] [Abstract][Full Text] [Related]
20. Processing of CD74 by the Intramembrane Protease SPPL2a Is Critical for B Cell Receptor Signaling in Transitional B Cells. Hüttl S; Kläsener K; Schweizer M; Schneppenheim J; Oberg HH; Kabelitz D; Reth M; Saftig P; Schröder B J Immunol; 2015 Aug; 195(4):1548-63. PubMed ID: 26157172 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]